Longitudinal “Real-World” Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece

BACKGROUND: Pirfenidone is an antifibrotic compound able to slow down disease progression in patients with idiopathic pulmonary fibrosis (IPF). OBJECTIVE: To investigate the safety and efficacy of pirfenidone in patients with IPF in a real-life setting. METHODS: This was a multicenter, retrospective...

Descripción completa

Detalles Bibliográficos
Autores principales: Tzouvelekis, Argyrios, Karampitsakos, Theodoros, Ntolios, Paschalis, Tzilas, Vasilios, Bouros, Evangelos, Markozannes, Evangelos, Malliou, Ioanna, Anagnostopoulos, Aris, Granitsas, Andreas, Steiropoulos, Paschalis, Dimakou, Katerina, Chrysikos, Serafeim, Koulouris, Nikolaos, Bouros, Demosthenes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5712559/
https://www.ncbi.nlm.nih.gov/pubmed/29238708
http://dx.doi.org/10.3389/fmed.2017.00213

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5712559/
https://www.ncbi.nlm.nih.gov/pubmed/29238708
http://dx.doi.org/10.3389/fmed.2017.00213

Ejemplares similares